Brief: Bempedoic Acid Met Primary Endpoint Of Phase 3 Trial In Japan For The Treatment For Hypercholesterolemia

Esperion Therapeutics

20/05/2024 11:09

Esperion Therapeutics Inc  ESPR.O :
    * BEMPEDOIC ACID MET PRIMARY ENDPOINT OF PHASE 3 TRIAL IN
JAPAN FOR THE TREATMENT FOR HYPERCHOLESTEROLEMIA
    * ESPERION THERAPEUTICS INC - TRIAL DEMONSTRATED
STATISTICALLY
SIGNIFICANT OUTCOMES ON PRIMARY ENDPOINT FOR BEMPEDOIC ACID
    * ESPERION THERAPEUTICS INC - OTSUKA PLANS TO SUBMIT AN NEW
DRUG
APPLICATION (NDA) IN JAPAN IN LATTER HALF OF 2024
    * ESPERION THERAPEUTICS INC - OTSUKA TO SUBMIT NEW DRUG
APPLICATION IN JAPAN IN LATTER HALF OF 2024

Source text for Eikon:  ID:nGNX7yj4DC 
Further company coverage:  ESPR.O